Mr. Marc Edwards reports

KANE BIOTECH ANNOUNCES ISSUANCE OF RESTRICTED SHARE UNITS

Kane Biotech Inc. has issued 9,703,809 restricted share units of the company to various directors, officers, employees and consultants of the company pursuant to the second amended and restated performance and restricted share unit plan of the company dated May 23, 2023. Each RSU is exercisable into one common share of the company. The RSUs will vest at different times, but none will vest earlier than 12 months from the date of grant.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets, and trademarks) and products developed by the company's own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech. The company is listed on the TSX Venture Exchange under the symbol KNE and on the OTCQB Venture Market under the symbol KNBIF.

We seek Safe Harbor.